Halozyme Therapeutics HALO Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $150.05M— | —— | $175.23M+6.1% | $165.16M+39.9% | $118.1M-13.8% | ||
| $4.22M+27.8% | $3.3M+22.4% | $2.7M0.0% | $2.7M+0.5% | $2.69M+1.3% | ||
| $16.64M+0.4% | $16.57M+36.3% | $12.16M0.0% | $12.16M+13.9% | $10.67M-6.9% | ||
| $180.08M-17.8% | $219.03M+22.6% | $178.6M+79.1% | $99.71M-35.3% | $154.22M-13.6% | ||
| $3.74M+162% | $1.43M-52.9% | $3.03M+93.9% | $1.56M+64.5% | $950K-68.9% | ||
| -$2.88M+99.6% | -$741.79M-468% | $201.61M— | —— | -$90.42M— | ||
| -$1.61M— | —— | -$22.4M+92.5% | -$298.97M-8,902% | -$3.32M+98.7% | ||
| $175.59M— | —— | $357.8M+413% | -$114.47M-289% | $60.48M+257% | ||
| $176.34M-19.0% | $217.6M+23.9% | $175.57M+78.9% | $98.15M-36.0% | $153.27M-12.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Halozyme Therapeutics generate?
- Halozyme Therapeutics (HALO) generated $677.4M in operating cash flow over the trailing twelve months.
- What is Halozyme Therapeutics's free cash flow?
- After $9.8M of capital expenditures, Halozyme Therapeutics's free cash flow was $667.7M over the trailing twelve months, up 34.7% year over year.
- Where does Halozyme Therapeutics's cash flow data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
